CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells

Cancer Letters

Volumn 306, Issue 1, 2011, Pages 43-51

  Rahimi, Massod ^a   Toth, Theodore A ^a   Tang, Careen K ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

CXCR4; EGFR; EGFRvIII; Growth; Invasion

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SHORT HAIRPIN RNA;

ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; PROTEIN VARIANT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CXCR4;

EID: 79955472668     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.024     Document Type: Article

References (32)

1. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
2. Andre F., Cabioglu N., Assi H., Sabourin J.C., Delaloge S., Sahin A., Broglio K., Spano J.P., Combadiere C., Bucana C., Soria J.C., Cristofanilli M. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann. Oncol. 2006, 17:945-951.
3. Blot E., Laberge-Le C.S., Jamali H., Cornic M., Guillemet C., Duval C., Hellot M.F., Pille J.Y., Picquenot J.M., Veyret C. CXCR4 membrane expression in node-negative breast cancer. Breast J. 2008, 14:268-274.
4. Cabioglu N., Sahin A., Doucet M., Yavuz E., Igci A., Yildirim O., Aktas E., Bilgic S., Kiran B., Deniz G., Price J.E. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin. Exp. Metastasis 2005, 22:39-46.
5. Cabioglu N., Yazici M.S., Arun B., Broglio K.R., Hortobagyi G.N., Price J.E., Sahin A. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin. Cancer Res. 2005, 11:5686-5693.
6. Cabioglu N., Gong Y., Islam R., Broglio K.R., Sneige N., Sahin A., Gonzalez-Angulo A.M., Morandi P., Bucana C., Hortobagyi G.N., Cristofanilli M. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann. Oncol. 2007, 18:1021-1029.
7. Cabioglu N., Sahin A.A., Morandi P., Meric-Bernstam F., Islam R., Lin H.Y., Bucana C.D., Gonzalez-Angulo A.M., Hortobagyi G.N., Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann. Oncol. 2009, 20:1013-1019.
8. Chu Q.D., Panu L., Holm N.T., Li B.D., Johnson L.W., Zhang S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J. Surg. Res. 2008.
9. Li Y.M., Pan Y., Wei Y., Cheng X., Zhou B.P., Tan M., Zhou X., Xia W., Hortobagyi G.N., Yu D., Hung M.C. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004, 6:459-469.
10. Liang Z., Wu T., Lou H., Yu X., Taichman R.S., Lau S.K., Nie S., Umbreit J., Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 2004, 64:4302-4308.
11. Tamamura H., Hori A., Kanzaki N., Hiramatsu K., Mizumoto M., Nakashima H., Yamamoto N., Otaka A., Fujii N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003, 550:79-83.
12. Tamamura H., Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin. Ther. Targets 2005, 9:1267-1282.
13. Chen Y., Stamatoyannopoulos G., Song C.Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res. 2003, 63:4801-4804.
14. Zhang M.X., Han N., Yu S.Y., Leng Y. Chemokine receptor CXCR4 gene silencing with shRNA inhibits breast cancer metastasis to the lung in nude mice. Zhonghua Zhong. Liu Za Zhi. 2008, 30:325-329.
15. Lapteva N., Yang A.G., Sanders D.E., Strube R.W., Chen S.Y. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther. 2005, 12:84-89.
16. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005, 65:967-971.
17. Yu H., Gong X., Luo X., Han W., Hong G., Singh B., Tang C.K. Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways. Cancer Biol. Ther. 2008, 7.
18. Silva H.A., Abraul E., Raimundo D., Dias M.F., Marques C., Guerra C., De Oliveira C.F., Regateiro F.J. Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. Eur. J. Cancer 2006, 42:2617-2622.
19. Silva H.C., Garcao F., Coutinho E.C., De Oliveira C.F., Regateiro F.J. Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells. Neoplasma 2006, 53:538-543.
20. Rahimi M., George J., Tang C. EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms. Int. J. Cancer 2009.
21. Lammering G., Valerie K., Lin P.S., Hewit T.H., Schmidt-Ullrich R.K. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother. Oncol. 2004, 72:267-273.
22. Tang C.K., Gong X.Q., Moscatello D.K., Wong A.J., Lippman M.E. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 2000, 60:3081-3087.
23. Cabioglu N., Summy J., Miller C., Parikh N.U., Sahin A.A., Tuzlali S., Pumiglia K., Gallick G.E., Price J.E. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res. 2005, 65:6493-6497.
24. Han W., Zhang T., Yu H., Foulke J.G., Tang C.K. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol. Ther. 2006, 5:1361-1368.
25. Adachi S., Natsume H., Yamauchi J., Matsushima-Nishiwaki R., Joe A.K., Moriwaki H., Kozawa O. p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047. Cancer Lett. 2009, 277:108-113.
26. Zwang Y., Yarden Y. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J. 2006, 25:4195-4206.
27. Benedetti V., Perego P., Luca B.G., Corna E., Tinelli S., Righetti S.C., Leone R., Apostoli P., Lanzi C., Zunino F. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol. Cancer Ther. 2008, 7:679-687.
28. Lavictoire S.J., Parolin D.A., Klimowicz A.C., Kelly J.F., Lorimer I.A. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J. Biol. Chem. 2003, 278:5292-5299.
29. Zhang Y., Su H., Rahimi M., Tochihara R., Tang C. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int. J. Cancer 2009, 125:2021-2028.
30. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., Weiss H., Rimawi M., Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008, 68:826-833.
31. Weppler S.A., Li Y., Dubois L., Lieuwes N., Jutten B., Lambin P., Wouters B.G., Lammering G. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother. Oncol. 2007, 83:333-339.
32. Lammering G., Valerie K., Lin P.S., Hewit T.H., Schmidt-Ullrich R.K. Radiation induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol. 2004, 72:267-273.